{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:18:35Z","timestamp":1787987915755,"version":"build-2784847793"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T00:00:00Z","timestamp":1702166400000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022282","name":"Universidad de Ciencias Aplicadas y Ambientales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022282","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.bpg.2023.101878","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T08:39:53Z","timestamp":1701419993000},"page":"101878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Prognostic models and autoimmune liver diseases"],"prefix":"10.1016","volume":"67","author":[{"given":"Daphne","family":"D'Amato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bpg.2023.101878_bib1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jhep.2013.09.020","article-title":"Autoimmune liver disease, autoimmunity and liver transplantation","volume":"60","author":"Carbone","year":"2014","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.bpg.2023.101878_bib2","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/tri.13358","article-title":"Annual report of the European liver transplant registry (ELTR) \u2013 50-year evolution of liver transplantation","volume":"31","author":"Adam","year":"2018","journal-title":"Transpl Int"},{"issue":"1","key":"10.1016\/j.bpg.2023.101878_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2023.101878_bib4","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bpg.2023.101878_bib5","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2023.101878_bib6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bpg.2023.101878_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gutjnl-2014-308351","article-title":"Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study","volume":"65","author":"Trivedi","year":"2016","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.bpg.2023.101878_bib8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.14218\/JCTH.2020.00006","article-title":"Hispanic patients with primary biliary cholangitis have decreased access to care compared to non-hispanics","volume":"8","author":"Rabiee","year":"2020","journal-title":"J Clin Transl Hepatol"},{"issue":"8","key":"10.1016\/j.bpg.2023.101878_bib9","first-page":"1333","article-title":"Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems","volume":"16","author":"Lu","year":"2018","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"8","key":"10.1016\/j.bpg.2023.101878_bib10","first-page":"1398","article-title":"Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics","volume":"12","author":"Levy","year":"2014","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"8","key":"10.1016\/j.bpg.2023.101878_bib11","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.cgh.2020.08.006","article-title":"Measurement of gamma glutamyl transferase to determine risk of liver transplantation or death in patients with primary biliary cholangitis","volume":"19","author":"Gerussi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2023.101878_bib12","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bpg.2023.101878_bib13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/gut.49.2.276","article-title":"Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant","volume":"49","author":"Vleggaar","year":"2001","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.bpg.2023.101878_bib14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jhep.2005.10.017","article-title":"Long term outcome and response to therapy of primary biliary cirrhosis\u2014autoimmune hepatitis overlap syndrome","volume":"44","author":"Chazouill\u00e8res","year":"2006","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2023.101878_bib15","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/hep.21172","article-title":"Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis","volume":"43","author":"Wesierska-Gadek","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bpg.2023.101878_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bpg.2023.101878_bib17","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.cgh.2010.03.004","article-title":"Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome","volume":"8","author":"Kuiper","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2023.101878_bib18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL clinical practice guidelines: liver transplantation","volume":"64","author":"Burra","year":"2016","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.bpg.2023.101878_bib19","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/apt.15533","article-title":"Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response","volume":"50","author":"Murillo Perez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bpg.2023.101878_bib20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/apt.15583","article-title":"Letter: histology is relevant for risk stratification in primary biliary cholangitis","volume":"51","author":"Carbone","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2023.101878_bib21","doi-asserted-by":"crossref","unstructured":"Ludwig J., Dickson E.R., McDonald G.S.A. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978 Aug 22;379(2):103-12. doi: 10.1007\/BF00432479. PMID: 150690.","DOI":"10.1007\/BF00432479"},{"issue":"2","key":"10.1016\/j.bpg.2023.101878_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0025-6196(11)63652-5","article-title":"Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis","volume":"73","author":"Scheuer","year":"1998","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.bpg.2023.101878_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1440-1827.2009.02500.x","article-title":"Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement","volume":"60","author":"Nakanuma","year":"2010","journal-title":"Pathol Int"},{"issue":"8","key":"10.1016\/j.bpg.2023.101878_bib24","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/17474124.2021.1945919","article-title":"A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients","volume":"15","author":"Hirschfield","year":"2021","journal-title":"Expet Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2023.101878_bib25","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII \u2013 renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2023.101878_bib26","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/hep.31810","article-title":"Accuracy of transient elastography in assessing fibrosis at diagnosis in na\u00efve patients with primary biliary cholangitis: a dual cut-off approach","volume":"74","author":"Cristoferi","year":"2021","journal-title":"Hepatology"},{"issue":"19","key":"10.1016\/j.bpg.2023.101878_bib27","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis","volume":"330","author":"Poupon","year":"1994","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bpg.2023.101878_bib28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bpg.2023.101878_bib29","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2023.101878_bib30","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bpg.2023.101878_bib31","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bpg.2023.101878_bib32","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2023.101878_bib33","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00535-009-0051-9","article-title":"Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis","volume":"44","author":"Azemoto","year":"2009","journal-title":"J Gastroenterol"},{"issue":"10","key":"10.1016\/j.bpg.2023.101878_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.bpg.2023.101878_bib35","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2023.101878_bib36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.26322","article-title":"Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study","volume":"58","author":"Zhang","year":"2013","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.bpg.2023.101878_bib37","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score","volume":"3","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2023.101878_bib38","doi-asserted-by":"crossref","unstructured":"Corpechot C., Carrat F., Gaouar F., Chau F., Gulamhusein A., Montano-loza A.J., et al. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. J Hepatol 2022.J Hepatol. 2022 Dec;77(6):1545-1553. doi: 10.1016\/j.jhep.2022.06.017. Epub 2022 Jun 28. PMID: 35777587.","DOI":"10.1016\/j.jhep.2022.06.017"},{"issue":"2","key":"10.1016\/j.bpg.2023.101878_bib39","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bpg.2023.101878_bib40","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis \u2013 a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2023.101878_bib41","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2009.11.046","article-title":"Genome-wide association analysis in primary sclerosing cholangitis","volume":"138","author":"Karlsen","year":"2010","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bpg.2023.101878_bib42","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3109\/00365521.2015.1036359","article-title":"Liver transplantation in the Nordic countries-An intention to treat and post-transplant analysis from the Nordic Liver Transplant Registry 1982-2013","volume":"50","author":"Fosby","year":"2015","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2023.101878_bib43","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jhep.2019.08.013","article-title":"Risk stratification in primary sclerosing cholangitis: it's time to move on from replicating imperfection and break the glass ceiling","volume":"71","author":"Trivedi","year":"2019","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2023.101878_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/gut.52.2.165","article-title":"Hepatic and extrahepatic malignancies and primary sclerosing cholangitis","volume":"52","author":"Schrumpf","year":"2003","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.bpg.2023.101878_bib45","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL clinical practice guidelines on sclerosing cholangitis","volume":"77","author":"Chazouilleres","year":"2022","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.bpg.2023.101878_bib46","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis","volume":"152","author":"Weism\u00fcller","year":"2017","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.bpg.2023.101878_bib47","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/j.gastro.2008.01.042","article-title":"The natural history of small-duct primary sclerosing cholangitis","volume":"134","author":"Bj\u00f6rnsson","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bpg.2023.101878_bib48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MCG.0b013e318157c614","article-title":"Characteristics and long-term prognosis of the autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome","volume":"43","author":"L\u00fcth","year":"2009","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2023.101878_bib49","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/hep.26977","article-title":"Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis","volume":"59","author":"Boonstra","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bpg.2023.101878_bib50","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.28256","article-title":"Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process","volume":"63","author":"Ponsioen","year":"2016","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bpg.2023.101878_bib51","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","article-title":"A revised natural history model for primary sclerosing cholangitis","volume":"75","author":"Kim","year":"2000","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.bpg.2023.101878_bib52","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/gutjnl-2016-313681","article-title":"A novel prognostic model for transplant-free survival in primary sclerosing cholangitis","volume":"67","author":"De Vries","year":"2018","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.bpg.2023.101878_bib53","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/hep.30479","article-title":"Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system","volume":"69","author":"Goode","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bpg.2023.101878_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/hep.30085","article-title":"Primary sclerosing cholangitis risk estimate tool (PREsTo) predicts outcomes of the disease: a derivation and validation study using machine learning","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bpg.2023.101878_bib55","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1055\/s-0043-107029","article-title":"Role of endoscopy in primary sclerosing cholangitis: European society of gastrointestinal endoscopy (ESGE) and European association for the study of the liver (EASL) clinical guideline","volume":"49","author":"Aabakken","year":"2017","journal-title":"Endoscopy"},{"issue":"9","key":"10.1016\/j.bpg.2023.101878_bib56","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1055\/s-0030-1255527","article-title":"Validation of a cholangiographic prognostic model in primary sclerosing cholangitis","volume":"42","author":"Ponsioen","year":"2010","journal-title":"Endoscopy"},{"issue":"13","key":"10.1016\/j.bpg.2023.101878_bib57","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1016\/j.cgh.2019.03.013","article-title":"Simple magnetic resonance scores associate with outcomes of patients with primary sclerosing cholangitis","volume":"17","author":"Lemoinne","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"July","key":"10.1016\/j.bpg.2023.101878_bib58","article-title":"Assessment of prognostic value and interreader agreement of ANALI scores in patients with primary sclerosing cholangitis","volume":"142","author":"Grigoriadis","year":"2021","journal-title":"Eur J Radiol"},{"issue":"12","key":"10.1016\/j.bpg.2023.101878_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2022.100595","article-title":"Development of a prognostic MRCP-score (DiStrict) for individuals with large-duct primary sclerosing cholangitis","volume":"4","author":"Grigoriadis","year":"2022","journal-title":"JHEP Reports"},{"issue":"4","key":"10.1016\/j.bpg.2023.101878_bib60","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/hep4.1860","article-title":"A quantitative magnetic resonance cholangiopancreatography metric of intrahepatic biliary dilatation severity detects high-risk primary sclerosing cholangitis","volume":"6","author":"Selvaraj","year":"2022","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.bpg.2023.101878_bib61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00330-021-08142-y","article-title":"Evaluation of quantitative MRCP (MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores","volume":"32","author":"Ismail","year":"2022","journal-title":"Eur Radiol"},{"issue":"11","key":"10.1016\/j.bpg.2023.101878_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2022.100577","article-title":"Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in people with primary sclerosing cholangitis","volume":"4","author":"Cazzagon","year":"2022","journal-title":"JHEP Reports"},{"issue":"3","key":"10.1016\/j.bpg.2023.101878_bib63","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.dld.2022.10.015","article-title":"A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis","volume":"55","author":"Cristoferi","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.bpg.2023.101878_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/hep.27825","article-title":"Enhanced liver fibrosis score predicts transplant\u2010free survival in primary sclerosing cholangitis","volume":"62","author":"Vesterhus","year":"2015","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.bpg.2023.101878_bib65","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/liv.13402","article-title":"Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study","volume":"37","author":"de Vries","year":"2017","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.bpg.2023.101878_bib66","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1053\/j.gastro.2013.12.030","article-title":"Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis","volume":"146","author":"Corpechot","year":"2014","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bpg.2023.101878_bib67","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.04.058","article-title":"Transient elastography in primary sclerosing cholangitis\u2014the value as a prognostic factor and limitations","volume":"147","author":"Ehlken","year":"2014","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bpg.2023.101878_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2021.100328","article-title":"Fluctuating biomarkers in primary sclerosing cholangitis: a longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF","volume":"3","author":"Fossdal","year":"2021","journal-title":"JHEP Reports"},{"key":"10.1016\/j.bpg.2023.101878_bib69","article-title":"Prospective validation of the prognostic value of liver stiffness (ls) assessed by fibroscan in primary sclerosing cholangitis (PSC): interim analysis of the FICUS study","volume":"70","author":"Chazouilleres","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bpg.2023.101878_bib70","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/liv.15286","article-title":"Impact on follow-up strategies in patients with primary sclerosing cholangitis","volume":"43","author":"Bergquist","year":"2023","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.bpg.2023.101878_bib71","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2022.11.011","article-title":"Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis","volume":"78","author":"Villard","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2023.101878_bib72","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jhep.2023.02.027","article-title":"Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis and prognostication of cholangiocarcinoma","volume":"79","author":"Lapitz","year":"2023","journal-title":"J Hepatol"},{"issue":"9902","key":"10.1016\/j.bpg.2023.101878_bib73","first-page":"1433","volume":"382","author":"Heneghan","year":"2013","journal-title":"Autoimmune hepatitis. Lancet"},{"issue":"5","key":"10.1016\/j.bpg.2023.101878_bib74","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2023.101878_bib75","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bpg.2023.101878_bib76","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/liv.15217","article-title":"Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group","volume":"42","author":"Lohse","year":"2022","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.bpg.2023.101878_bib77","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","author":"Lohse","year":"2015","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2023.101878_bib78","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/hep.24141","article-title":"Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis","volume":"53","author":"Yeoman","year":"2011","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bpg.2023.101878_bib79","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.cgh.2019.11.013","article-title":"Rapid response to treatment of autoimmune hepatitis associated with remission at 6 and 12 months","volume":"18","author":"Pape","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2023.101878_bib80","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.20732","article-title":"Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome","volume":"42","author":"Feld","year":"2005","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bpg.2023.101878_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/hep.27983","article-title":"Prediction of short\u2010 and long\u2010term outcome in patients with autoimmune hepatitis","volume":"62","author":"Kirstein","year":"2015","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bpg.2023.101878_bib82","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1053\/j.gastro.2011.02.065","article-title":"Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center","volume":"140","author":"Hoeroldt","year":"2011","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bpg.2023.101878_bib83","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jhep.2016.12.003","article-title":"EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure","volume":"66","author":"Wendon","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2023.101878_bib84","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jhep.2020.12.033","article-title":"Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: the SURFASA score","volume":"74","author":"De Martin","year":"2021","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.bpg.2023.101878_bib85","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.autrev.2018.02.013","article-title":"Support of precision medicine through risk-stratification in autoimmune liver diseases \u2013 histology, scoring systems, and non-invasive markers","volume":"17","author":"Bossen","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.bpg.2023.101878_bib86","article-title":"The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease","volume":"99","author":"Adams","year":"2004","journal-title":"Off J Am Coll Gastroenterol | ACG"},{"issue":"9","key":"10.1016\/j.bpg.2023.101878_bib87","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1007\/s10620-016-4213-3","article-title":"Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease","volume":"61","author":"De Luca-Johnson","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bpg.2023.101878_bib88","doi-asserted-by":"crossref","unstructured":"Ciardullo S., Carbone M., Invernizzi P., Perseghin G. Exploring the landscape of steatotic liver disease in the general US population. Liver Int Off J Int Assoc Study Liver 2023 Aug.Liver Int. 2023 Nov;43(11):2425-2433. doi: 10.1111\/liv.15695. Epub 2023 Aug 17. PMID: 37592856.","DOI":"10.1111\/liv.15695"},{"issue":"December 2019","key":"10.1016\/j.bpg.2023.101878_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.02.001","article-title":"NAFLD and autoimmune hepatitis: do not judge a book by its cover","volume":"75","author":"Dalekos","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"5","key":"10.1016\/j.bpg.2023.101878_bib90","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jhep.2023.01.013","article-title":"Long-term outcomes of patients with type 1 or 2 autoimmune hepatitis presenting in childhood","volume":"78","author":"Maggiore","year":"2023","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.bpg.2023.101878_bib91","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/apt.13210","article-title":"Type 1 and type 2 autoimmune hepatitis in adults share the same clinical phenotype","volume":"41","author":"Muratori","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bpg.2023.101878_bib92","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jhep.2021.12.041","article-title":"Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group","volume":"76","author":"Pape","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2023.101878_bib93","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bpg.2023.101878_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2020.100149","article-title":"Approach to the patient with acute severe autoimmune hepatitis","volume":"2","author":"Rahim","year":"2020","journal-title":"JHEP Reports"},{"issue":"6","key":"10.1016\/j.bpg.2023.101878_bib95","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/lt.25451","article-title":"Acute severe autoimmune hepatitis: corticosteroids or liver transplantation?","volume":"25","author":"Rahim","year":"2019","journal-title":"Liver Transplant"},{"issue":"November","key":"10.1016\/j.bpg.2023.101878_bib96","first-page":"1","article-title":"Artificial intelligence for precision medicine in autoimmune liver disease","volume":"13","author":"Gerussi","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.bpg.2023.101878_bib97","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jhep.2017.11.020","article-title":"Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis","volume":"68","author":"Hartl","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2023.101878_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214921","article-title":"Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver","volume":"14","author":"Bachtiar","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bpg.2023.101878_bib99","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/hep4.1687","article-title":"Multiparametric magnetic resonance imaging, autoimmune hepatitis, and prediction of disease activity","volume":"5","author":"Arndtz","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.bpg.2023.101878_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101325","article-title":"Quantitative magnetic resonance imaging to aid clinical decision making in autoimmune hepatitis","volume":"46","author":"Heneghan","year":"2022","journal-title":"eClinicalMedicine"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691823000641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691823000641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:05:34Z","timestamp":1761498334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691823000641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":100,"alternative-id":["S1521691823000641"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2023.101878","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic models and autoimmune liver diseases","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2023.101878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101878"}}